Q3 2024 Lexicon Pharmaceuticals Inc Earnings Call Transcript

Nov 12, 2024 / 10:00 PM GMT

Release Date Price: $1.19 (-6.30%)

Transcript 10-Q8-K

Key Points

Positve

Lexicon Pharmaceuticals Inc (LXRX) completed the resubmission of their NDA for inep for glycemic control in people with type one diabetes and chronic kidney disease.
The company has two major assets undergoing late-stage clinical development, with significant progress in both a phase three study for Solosin in hypertrophic cardiomyopathy and a phase two B study for LX 9,211 in diabetic peripheral neuropathic pain.
Lexicon Pharmaceuticals Inc (LXRX) has entered into an exclusive licensing agreement with Beatrice for Sogo Flozin outside of the US and Europe, providing a $25 million upfront payment and potential milestone payments.
The company has a strong cash position with $258.4 million in cash and investments, not including the recent $25 million from the Beatrice deal.
Lexicon Pharmaceuticals Inc (LXRX) is actively preparing for an IND filing for their novel drug candidate LX 9,851, targeting obesity and associated cardiometabolic disorders, by mid-2025.

Negative

The advisory committee voted 11 to 3 that the benefits of Zinque do not outweigh the risks in adults with type one diabetes and chronic kidney disease.
Net sales for the third quarter of 2024 were only $1.7 million, representing modest growth and highlighting challenges in commercial performance.
R&D expenses increased significantly to $25.8 million from $17.6 million in the corresponding period of 2023, primarily due to investments in late-stage development programs.
Selling, general, and administrative expenses rose to $39.6 million from $32.2 million, reflecting higher marketing costs and severance costs from strategic repositioning.
Lexicon Pharmaceuticals Inc (LXRX) faces challenges in gaining FDA approval for their products, with ongoing discussions and uncertainty around potential outcomes.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LXRX.OQ - Lexicon Pharmaceuticals Inc
Q3 2024 Lexicon Pharmaceuticals Inc Earnings Call
Nov 12, 2024 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the Lexicon Pharmaceuticals third quarter, 2024 results conference call. All participants will be in listen-only mode. Should you need assistance? Please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions to ask a question. You may press star, then one on a touchtone phone to withdraw your question. Please press star and then two.

Please note this event is being recorded. I would now like to turn the conference over to Lisa Steve Francesco, Head of Investor Relations and corporate Communications. Please go ahead.

------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.